Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

Affiliations

• ¹ Department of Pathology and Laboratory Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA, USA.
• ² Section of Infectious Diseases and International Medicine, Department of Internal Medicine, Beaumont Royal Oak, Royal Oak, MI, USA.
• ³ Departments of Internal Medicine and Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI, USA.
• ⁴ Western University, London, ON, Canada.
• ⁵ Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
• ⁶ Division of Digestive Disease, Yale University School of Medicine, New Haven, CT, USA.
• ⁷ PACT-Gastroenterology Center, Hamden, CT, USA.
• ⁸ Department of Gastroenterology, Palo Alto Medical Foundation, Sutter Health, Mountain View, CA, USA.
• ⁹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
• ¹⁰ University at Buffalo, VA Western New York Healthcare System, Buffalo, NY, USA.
• ¹¹ Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA.
• ¹² University of California Davis Health, Sacramento, CA, USA.
• ¹³ Gastroenterology and Hepatology, Chevy Chase Clinical Research, Chevy Chase, MD, USA.
• ¹⁴ Island Medical Program, University of British Columbia and University of Victoria, Vancouver, BC, Canada.
• ¹⁵ Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.
• ¹⁶ Adventist Health, Simi Valley, CA, USA.
• ¹⁷ Brody School of Medicine at East, Carolina University, Greenville, NC, USA.
• ¹⁸ Cleveland Clinic, Cleveland, OH, USA.
• ¹⁹ Division of Infectious Diseases, Henry Ford Health, Detroit, MI, USA.
• ²⁰ Division of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center, Washington, DC, USA.
• ²¹ Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA. [email protected].